Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

WEDNESDAY, Nov. 30, 2022 -- For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news